NCT03059030

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Northwestern University · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the safety and efficacy of Yttrium-90 (90Y) radioembolization for the management of thrombocytopenia.

Detailed description

This protocol will provide access to TheraSphere® treatment for patients who have refractory thrombocytopenia secondary to cirrhosis. This protocol will utilize splenic artery-directed TheraSphere® treatment.

Conditions

• Thrombocytopenia
• Cirrhosis

Interventions

Type	Name	Description
DEVICE	TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.	The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.

Timeline

• Start date: 2017-03-16
• Primary completion: 2024-04-04
• Completion: 2024-04-04
• First posted: 2017-02-23
• Last updated: 2025-02-03
• Results posted: 2025-02-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study